Author

Hyshem H. Lancia

Harvard UniversityORCID 0000-0002-9895-4552Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Caroline M. Coletti· 1 shared David PépiniD· 1 shared Estelle Tromelin· 1 shared Henri‐Alexandre MichaudiD· 1 shared Julien Roche-PrellezoiD· 1 shared Laurent GrosiD· 1 shared Maeva Y. ChauviniD· 1 shared Marie-Charlotte MeinsohniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Caroline M. Coletti

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

FSTL3 is a biomarker of poor prognosis and is associated with immunotherapy resistance in ovarian cancer.

Maeva Y. Chauvin, Estelle Tromelin, Julien Roche-Prellezo, Hyshem H. Lancia, Marie-Charlotte Meinsohn, Caroline M. Coletti, Ngoc Minh Nguyen, Virginie Lafont, Henri‐Alexandre Michaud, Ranjan Kumar Mishra, Laurent Gros, Nathalie Bonnefoy, David Pépin

This study identifies FSTL3 as a biomarker of poor prognosis and immunotherapy resistance in ovarian cancer, showing its role in promoting a mesenchymal phenotype and immunosuppressive microenvironment.

Journal of Experimental & Clinical Cancer Research · Sep 30, 2025Peer-reviewedCancer Biology